CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Molnupiravir

莫诺拉韦 杂质对照品Molnupiravir Impurities

44 个杂质条目44 impurity entries

本页汇总 莫诺拉韦 的 44 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 44 impurity reference standards of Molnupiravir. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 莫诺拉韦(Molnupiravir)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesA sensitive UPLC-MS/MS method for the simultaneous assay and trace level genotoxic impurities quantification of SARS-CoV-2 inhibitor-Molnupiravir in its pure and formulation dosage forms using fractional factorial design
    Results in chemistry · 2023 · Nakka S et al.  ·  PMID 37396150  ·  DOI
  2. 杂质研究Impurity studiesStructure Elucidation and In Silico Safety Assessment of a Degradation Impurity in Molnupiravir Capsule Formulation: Development of a Stability-Indicating Method for Related Substances
    Journal of AOAC International · 2026 · Patel R et al.  ·  PMID 40929093  ·  DOI
  3. 杂质研究Impurity studiesStability Indicating High Performance Liquid Chromatography Method Development, Validation, and Characterization of Forced Degradant Product by Liquid Chromatography-Mass Spectroscopy for Molnupiravir and Favipiravir
    Journal of chromatographic science · 2025 · Pethani TM et al.  ·  PMID 40152015  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisSynthesis of molnupiravir (MK-4482, EIDD-2801): a promising oral drug for the treatment of COVID-19 starting from cytidine
    Nucleosides, nucleotides & nucleic acids · 2023 · Venkatanarayana P et al.  ·  PMID 36472346  ·  DOI
  • 合成方法SynthesisConcise two-step chemical synthesis of molnupiravir
    RSC advances · 2022 · Pereira VRD et al.  ·  PMID 36329948  ·  DOI

莫诺拉韦 —— 原料药与杂质对照品Molnupiravir — drug substance & impurities

共 44 个条目(含原料药本体)44 items incl. the drug substance
Molnupiravir IP Impurity L structure
L
莫诺拉韦IP杂质LMolnupiravir IP Impurity L
Molnupiravir IP Impurity L
CAS No.886538-46-1
Chemical FormulaC9H13N3O6
Purity>95%现货In stock
10mg25mg50mg100mg
Molnupiravir Impurity 1 structure
1
莫诺拉韦杂质1Molnupiravir Impurity 1
Molnupiravir Impurity 1
CAS No.3258-02-4
Chemical FormulaC9H13N3O6
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 3 structure
3
莫诺拉韦杂质3Molnupiravir Impurity 3
Molnupiravir Impurity 3
CAS No.1686124-74-2
Chemical FormulaC16H23N3O6
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 4 structure
4
莫诺拉韦杂质4Molnupiravir Impurity 4
Molnupiravir Impurity 4
CAS No.2346620-55-9
Chemical FormulaC16H23N3O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 6 structure
6
莫诺拉韦杂质6Molnupiravir Impurity 6
Molnupiravir Impurity 6
CAS No.20555-88-8
Chemical FormulaC4H5N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 7 structure
7
莫诺拉韦杂质7Molnupiravir Impurity 7
Molnupiravir Impurity 7
CAS No.2591381-21-2
Chemical FormulaC9H16O6
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 8 structure
8
莫诺拉韦杂质8Molnupiravir Impurity 8
Molnupiravir Impurity 8
CAS No.13491-41-3
Chemical FormulaC9H13N3O6
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 10 structure
10
莫诺拉韦杂质10Molnupiravir Impurity 10
Molnupiravir Impurity 10
CAS No.402725-23-9
Chemical FormulaC9H13N3O6
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 11 structure
11
莫诺拉韦杂质11Molnupiravir Impurity 11
Molnupiravir Impurity 11
CAS No.886538-48-3
Chemical FormulaC13H18N2O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 12 ((E)-Molnupiravir) structure
12
莫诺拉韦杂质12 ((E)-莫诺拉韦)Molnupiravir Impurity 12 ((E)-Molnupiravir)
Molnupiravir Impurity 12 ((E)-Molnupiravir)
CAS No.2492423-30-8
Chemical FormulaC13H19N3O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 13 structure
13
莫诺拉韦杂质13Molnupiravir Impurity 13
Molnupiravir Impurity 13
CAS No.362-42-5
Chemical FormulaC12H17N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 14 structure
14
莫诺拉韦杂质14Molnupiravir Impurity 14
Molnupiravir Impurity 14
CAS No.2346620-54-8
Chemical FormulaC18H23N5O6
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 15 structure
15
莫诺拉韦杂质15Molnupiravir Impurity 15
Molnupiravir Impurity 15
CAS No.20541-50-8
Chemical FormulaC5H7N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 16 structure
16
莫诺拉韦杂质16Molnupiravir Impurity 16
Molnupiravir Impurity 16
CAS No.2346620-53-7
Chemical FormulaC16H22N2O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 17 structure
17
莫诺拉韦杂质17Molnupiravir Impurity 17
Molnupiravir Impurity 17
CAS No.362-43-6
Chemical FormulaC12H16N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 18 structure
18
莫诺拉韦杂质18Molnupiravir Impurity 18
Molnupiravir Impurity 18
CAS No.2635324-86-4
Chemical FormulaC13H19N3O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 19 structure
19
莫诺拉韦杂质19Molnupiravir Impurity 19
Molnupiravir Impurity 19
CAS No.2346620-24-2
Chemical FormulaC14H21N3O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 20 structure
20
莫诺拉韦杂质20Molnupiravir Impurity 20
Molnupiravir Impurity 20
CAS No.2346620-25-3
Chemical FormulaC14H21N3O8
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 21 structure
21
莫诺拉韦杂质21Molnupiravir Impurity 21
Molnupiravir Impurity 21
CAS No.2346620-22-0
Chemical FormulaC17H27N3O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 22 structure
22
莫诺拉韦杂质22Molnupiravir Impurity 22
Molnupiravir Impurity 22
CAS No.2346620-18-4
Chemical FormulaC13H17N3O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 23 structure
23
莫诺拉韦杂质23Molnupiravir Impurity 23
Molnupiravir Impurity 23
CAS No.2591421-26-8
Chemical FormulaC19H35N3O7Si2
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 24 structure
24
莫诺拉韦杂质24Molnupiravir Impurity 24
Molnupiravir Impurity 24
CAS No.2346620-19-5
Chemical FormulaC14H19N3O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 25 structure
25
莫诺拉韦杂质25Molnupiravir Impurity 25
Molnupiravir Impurity 25
CAS No.2346620-20-8
Chemical FormulaC15H21N3O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 26 structure
26
莫诺拉韦杂质26Molnupiravir Impurity 26
Molnupiravir Impurity 26
CAS No.2684302-84-7
Chemical FormulaC17H25N3O8
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 27 structure
27
莫诺拉韦杂质27Molnupiravir Impurity 27
Molnupiravir Impurity 27
CAS No.2759996-71-7
Chemical FormulaC13H18FN3O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 28 structure
28
莫诺拉韦杂质28Molnupiravir Impurity 28
Molnupiravir Impurity 28
CAS No.2346620-21-9
Chemical FormulaC16H23N3O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 29 structure
29
莫诺拉韦杂质29Molnupiravir Impurity 29
Molnupiravir Impurity 29
CAS No.2491727-03-6
Chemical FormulaC14H18N4O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 30 structure
30
莫诺拉韦杂质30Molnupiravir Impurity 30
Molnupiravir Impurity 30
CAS No.2346619-88-1
Chemical FormulaC21H31N3O9
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 31 structure
31
莫诺拉韦杂质31Molnupiravir Impurity 31
Molnupiravir Impurity 31
CAS No.2346619-93-8
Chemical FormulaC24H37N3O9
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 32 structure
32
莫诺拉韦杂质32Molnupiravir Impurity 32
Molnupiravir Impurity 32
CAS No.2346619-90-5
Chemical FormulaC33H55N3O9
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 33 structure
33
莫诺拉韦杂质33Molnupiravir Impurity 33
Molnupiravir Impurity 33
CAS No.2346619-94-9
Chemical FormulaC24H37N3O12
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 34 structure
34
莫诺拉韦杂质34Molnupiravir Impurity 34
Molnupiravir Impurity 34
CAS No.2639393-05-6
Chemical FormulaC16H23N3O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 35 structure
35
莫诺拉韦杂质35Molnupiravir Impurity 35
Molnupiravir Impurity 35
CAS No.2759996-93-3
Chemical FormulaC14H17N3O8
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 36 structure
36
莫诺拉韦杂质36Molnupiravir Impurity 36
Molnupiravir Impurity 36
CAS No.2759996-74-0
Chemical FormulaC21H30FN3O9
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 37 structure
37
莫诺拉韦杂质37Molnupiravir Impurity 37
Molnupiravir Impurity 37
CAS No.2346619-80-3
Chemical FormulaC21H25N3O9
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 38 structure
38
莫诺拉韦杂质38Molnupiravir Impurity 38
Molnupiravir Impurity 38
CAS No.2346619-82-5
Chemical FormulaC24H31N3O9
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 39 structure
39
莫诺拉韦杂质39Molnupiravir Impurity 39
Molnupiravir Impurity 39
CAS No.2346619-84-7
Chemical FormulaC27H37N3O9
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 40 structure
40
莫诺拉韦杂质40Molnupiravir Impurity 40
Molnupiravir Impurity 40
CAS No.2346619-86-9
Chemical FormulaC30H43N3O9
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 41 structure
41
莫诺拉韦杂质41Molnupiravir Impurity 41
Molnupiravir Impurity 41
CAS No.2491727-32-1
Chemical FormulaC38H40N4O9
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 47 structure
47
莫诺拉韦杂质47Molnupiravir Impurity 47
Molnupiravir Impurity 47
CAS No.1955522-18-5
Chemical FormulaC12H17N3O6
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 48 (Mixture of Isomers) structure
48
莫诺拉韦杂质48 (混合E/Z构型)Molnupiravir Impurity 48 (Mixture of Isomers)
Molnupiravir Impurity 48 (Mixture of Isomers)
CAS No.2346619-14-3
Chemical FormulaC14H22N4O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 50 (Mixture of E/Z-isomers) structure
50
莫诺拉韦杂质50 (混合E/Z构型)Molnupiravir Impurity 50 (Mixture of E/Z-isomers)
Molnupiravir Impurity 50 (Mixture of E/Z-isomers)
CAS No.2770244-32-9
Chemical FormulaC13H19N3O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 54 structure
54
莫诺拉韦杂质54Molnupiravir Impurity 54
Molnupiravir Impurity 54
CAS No.2920217-28-1
Chemical FormulaC13H19N3O7
Purity>95%询价On request
10mg25mg50mg100mg
Molnupiravir Impurity 55 (Mixture of E/Z-isomers) structure
55
莫诺拉韦杂质55 (混合E/Z构型)Molnupiravir Impurity 55 (Mixture of E/Z-isomers)
Molnupiravir Impurity 55 (Mixture of E/Z-isomers)
CAS No.2684302-85-8
Chemical FormulaC13H19N3O7
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

莫诺拉韦 —— 研究文献与合成路线Molnupiravir — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 莫诺拉韦 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Molnupiravir. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Stability Indicating High Performance Liquid Chromatography Method Development, Validation, and Characterization of Forced Degradant Product by Liquid Chromatography-Mass Spectroscopy for Molnupiravir and Favipiravir
    Pethani TM, Sangani M, Santoki PS · Journal of chromatographic science · 2025
  2. A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies
    Reçber T, Timur SS, Erdoğan Kablan S, et al. · Journal of pharmaceutical and biomedical analysis · 2022 · 被引 22cited 22
  3. A sustainable approach for the degradation kinetics study and stability assay of the SARS-CoV-2 oral antiviral drug Molnupiravir
    Edrees FH, Draz ME, Saad AS, et al. · Scientific reports · 2023 · 被引 4cited 4
  4. White targeted chromatographic screening method of Molnupiravir and its metabolite with degradation kinetics characterization and in-silico toxicity
    Aboras SI, Megahed AA, El-Yazbi F, et al. · Scientific reports · 2023 · 被引 6cited 6
  5. A sensitive UPLC-MS/MS method for the simultaneous assay and trace level genotoxic impurities quantification of SARS-CoV-2 inhibitor-Molnupiravir in its pure and formulation dosage forms using fractional factorial design
    Nakka S, Muchakayala SK, Manabolu Surya SB · Results in chemistry · 2023 · 被引 4cited 4
  6. Hyphenating sustainability with chemometrics in chromatographic analysis of COVID combo therapy, nirmatrelvir and Molnupiravir, in presence of their overlapping degradation products; blue-green dual evaluation tools
    Aboras SI, Korany MA, Ebied SA, et al. · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2024 · 被引 2cited 2

合成路线文献Synthetic-route papers

  1. Copy-back RNA synthesis by coronavirus polymerase requires helicase activity and is stimulated by remdesivir and molnupiravir
    Rakib A, Das A, Bera SC, et al. · Science advances · 2026
  2. Divergent sustainability profiles of molnupiravir synthesis routes are governed by solvent use and process design
    Chen Z, Lian JZ, Huang H, et al. · Proceedings of the National Academy of Sciences of the United States of America · 2025
  3. From Batch to Continuous Flow Synthesis in Enzymatic Process Towards Molnupiravir
    Hongnak S, Vorasin O, Aunbamrung P, et al. · Chemistry, an Asian journal · 2025

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

莫诺拉韦 杂质谱研究要点Molnupiravir — impurity profiling notes

下面这些是拿到 莫诺拉韦 的 44 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 44 impurity entries for Molnupiravir, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances